MedPath

OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.otsuka-us.com

A Single-blind, Placebo-controlled, Outpatient Trial to Assess the Effects of Single Oral Tablet Dose of OPC-214870

Phase 1
Completed
Conditions
Epilepsy
Interventions
Other: Placebo
First Posted Date
2020-01-27
Last Posted Date
2022-08-24
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
16
Registration Number
NCT04241965
Locations
🇺🇸

For additional information regarding sites, contact 844-687-8522, Ormond Beach, Florida, United States

Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD)

Phase 2
Completed
Conditions
Borderline Personality Disorder
Interventions
First Posted Date
2019-12-04
Last Posted Date
2024-10-03
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
201
Registration Number
NCT04186403
Locations
🇺🇸

For additional information regarding sites, contact 844-687-8522, New York, New York, United States

Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder

Phase 3
Completed
Conditions
Post Traumatic Stress Disorder
Interventions
First Posted Date
2019-11-22
Last Posted Date
2025-05-30
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
591
Registration Number
NCT04174170
Locations
🇺🇸

For additional information regarding sites, contact 844-687-8522, New York, New York, United States

Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder

Phase 3
Completed
Conditions
Irritability Associated With Autism Spectrum Disorder (ASD)
Interventions
Drug: Placebo
First Posted Date
2019-11-22
Last Posted Date
2023-08-14
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
119
Registration Number
NCT04174365
Locations
🇺🇸

For additional information regarding sites, Princeton, New Jersey, United States

Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD

Phase 3
Completed
Conditions
Post Traumatic Stress Disorder
Interventions
First Posted Date
2019-10-11
Last Posted Date
2025-06-13
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
450
Registration Number
NCT04124614
Locations
🇺🇸

For additional information regarding sites, contact 844-687-8522, San Diego, California, United States

A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.

Phase 3
Completed
Conditions
Schizophrenia
Interventions
First Posted Date
2019-10-04
Last Posted Date
2024-06-28
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
475
Registration Number
NCT04115319
Locations
🇺🇸

Synexus Clinical Research US, Inc., Cerritos, California, United States

🇺🇸

Pacific Research Partners, Oakland, California, United States

🇺🇸

Excell Research, Oceanside, California, United States

and more 43 locations

A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia

Phase 3
Terminated
Conditions
Schizophrenia
Interventions
First Posted Date
2019-10-01
Last Posted Date
2024-12-16
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
463
Registration Number
NCT04109950
Locations
🇺🇦

Research Site, Vinnytsia, Ukraine

A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder

Phase 2
Completed
Conditions
Borderline Personality Disorder
Interventions
Other: Placebo
First Posted Date
2019-09-24
Last Posted Date
2024-07-18
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
332
Registration Number
NCT04100096
Locations
🇺🇸

Pillar Clinical Research, Richardson, Texas, United States

🇺🇸

CI Trials, Santa Ana, California, United States

🇺🇸

Care Access Research Beverly Hills, Beverly Hills, California, United States

and more 72 locations

A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

Phase 3
Completed
Conditions
Schizophrenia
Interventions
First Posted Date
2019-09-17
Last Posted Date
2024-06-26
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
464
Registration Number
NCT04092686
Locations
🇺🇸

Woodland Research Northwest, Rogers, Arkansas, United States

🇺🇸

Advanced Research Center, Inc., Anaheim, California, United States

🇺🇸

Clinical Innovations, Inc., Bellflower, California, United States

and more 58 locations

Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)

Phase 2
Completed
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
First Posted Date
2019-09-09
Last Posted Date
2023-01-13
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
13
Registration Number
NCT04081363
Locations
🇺🇸

For additional information regarding sites, contact 844-687-8522, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath